The efficacy of postoperative radiotherapy in resected pⅢA-N2 EGFR mutant and wild-type lung adenocarcinoma

• Published in: iScience Vol. 27; no. 7; p. 110219
• Main Authors: Zeng, Yue, Pu, Xing-Xiang, He, Feng-Jiao, Hu, Chun-Hong, Zhu, Hong, Huang, Yan, Peng, Yu-Rong, Zou, Ji-An, Liu, Jun-Qi, Shi, Sheng-Hao, Liu, Yue-Fei, Ma, Fang, Deng, Chao, Qiu, Zhen-Hua, Li, Yan-Long, Zhang, Ying-Zhe, Huang, Kun, Liu, Xian-Ling, Wu, Fang
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 19.07.2024; Elsevier
• Subjects: Cancer; Disease; Therapy; Disease; Therapy; Cancer
• ISSN: 2589-0042; 2589-0042
• DOI: 10.1016/j.isci.2024.110219

The resected pⅢA-N2 non-small-cell lung cancer (NSCLC) patients who could benefit from postoperative radiotherapy (PORT) are not well-defined. The study explored the role of PORT on EGFR mutant and wild-type NSCLC patients. We retrospectively searched for resected pIIIA-N2 lung adenocarcinoma patients who underwent EGFR mutation testing. 80 patients with EGFR wild-type and 85 patients with EGFR mutation were included. 62 patients received PORT. In overall population, the median disease-free survival (DFS) was improved in PORT arm compared to non-PORT arm (22.9 vs. 16.1 months; p = 0.036), along with higher 2-year locoregional recurrence-free survival (LRFS) rate (88.3% vs. 69.3%; p = 0.004). In EGFR wild-type patients, PORT was associated with a longer median DFS (23.3 vs. 17.2 months; p = 0.044), and a higher 2-year LRFS rate (86.8% vs. 61.9%; p = 0.012). In EGFR mutant patients, PORT was not significantly correlated with improved survival outcomes. EGFR wild-type may a biomarker to identify the cohort that benefits from PORT. [Display omitted] •DFS was improved in both overall and EGFR wild-type patients receiving PORT•PORT was not correlated with improved survival outcomes in EGFR mutation patients•EGFR wild-type may a biomarker to identify the cohort that benefits from PORT Disease; Therapy; Cancer